Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Income Statement [Abstract]
Net sales	$ 5,065	$ 4,209	$ 14,788	$ 12,186
Cost of products sold (excluding amortization expense)	1,523	1,312	4,613	3,791
Gross profit	3,542	2,897	10,175	8,395
Operating expenses:
Selling, general and administrative expenses	1,741	1,562	5,053	4,372
Research and development expenses	514	407	1,483	1,156
Royalty expense	12	5	40	24
Amortization expense	225	205	669	631
Intangible asset impairment charges	0	0	46	276
Contingent consideration net expense (benefit)	11	(23)	11	(4)
Restructuring net charges (credits)	(8)	8	85	12
Operating expenses	2,494	2,164	7,387	6,467
Operating income (loss)	1,048	733	2,788	1,928
Other income (expense):
Interest expense	(87)	(79)	(259)	(225)
Other, net	(23)	14	156	(7)
Income (loss) before income taxes	939	669	2,685	1,697
Income tax expense (benefit)	183	200	463	413
Net income (loss)	755	468	2,222	1,284
Net income (loss) attributable to noncontrolling interests	0	0	(4)	(4)
Net income (loss) attributable to Boston Scientific common stockholders	$ 755	$ 469	$ 2,226	$ 1,288
Net income (loss) per common share — basic	$ 0.51	$ 0.32	$ 1.50	$ 0.88
Net income (loss) per common share — diluted	$ 0.51	$ 0.32	$ 1.49	$ 0.87
Weighted-average shares outstanding
Basic	1,481.7	1,472.7	1,479.6	1,470.6
Diluted	1,495.5	1,487.4	1,494.0	1,484.5